The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 15, 2015

Filed:

Oct. 25, 2013
Applicant:

Healthpartners Research Foundation, Bloomington, MN (US);

Inventors:

William H. Frey, II, White Bear Lake, MN (US);

Samuel Scott Panter, San Francisco, CA (US);

Leah Ranae Bresin Hanson, Vadnais Heights, MN (US);

Assignee:

HealthPartners Research Foundation, Bloomington, MN (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/30 (2006.01); A61K 38/04 (2006.01); A61K 31/16 (2006.01); A61K 9/00 (2006.01); A61K 31/165 (2006.01); A61K 31/195 (2006.01); A61K 38/18 (2006.01); A61K 38/20 (2006.01); A61K 38/28 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/16 (2013.01); A61K 9/0043 (2013.01); A61K 31/165 (2013.01); A61K 31/195 (2013.01); A61K 38/1841 (2013.01); A61K 38/2006 (2013.01); A61K 38/28 (2013.01); A61K 38/30 (2013.01); A61K 45/06 (2013.01);
Abstract

Methods for preconditioning, treating and/or providing neuroprotection to the animal central nervous system against the effects of neurodegeneration caused by iron accumulation in the brain. Therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. An examplary therapeutic agent is the iron chelator deferoxamine (DFO). An effective amount of DFO may be administered to the upper third of the nasal cavity of a patient at risk for or diagnosed with neurodegeneration caused by iron accumulation in the brain. The effective amount of DFO is delivered directly to the patient's central nervous system for preconditioning, preventing and/or treating neurodegeneration caused by iron accumulation in the brain.


Find Patent Forward Citations

Loading…